The Use of Oral Budesonide in Adolescents and Adults With Protein-Losing Enteropathy After the Fontan Operation

Size: px
Start display at page:

Download "The Use of Oral Budesonide in Adolescents and Adults With Protein-Losing Enteropathy After the Fontan Operation"

Transcription

1 ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at To take the CME activity related to this article, you must have either an STS member or an individual non-member subscription to the journal. The Use of Oral Budesonide in Adolescents and Adults With Protein-Losing Enteropathy After the Fontan Operation Anitha S. John, MD, PhD, David J. Driscoll, MD, Carole A. Warnes, MD, FRCP, Sabrina D. Phillips, MD, and Frank Cetta, MD Division of Pediatric Cardiology, Children s National Medical Center, George Washington University, Washington, DC; and Divisions of Cardiovascular Diseases and Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota Background. Approximately 5% to 15% of patients develop protein-losing enteropathy (PLE) after the Fontan operation. Oral controlled release (CR) budesonide has been used as a treatment strategy, but its use in the older Fontan population has not been described. Methods. Seven patients with refractory PLE after the Fontan operation were started on oral CR-budesonide at 9 mg. After 3 to 9 months, the dose was weaned to 3 mg. Response to treatment was assessed by clinical evaluation, serum albumin levels, and fecal -1 antitrypsin clearance when available. Results. Median age at last evaluation was 20 years (range, 16 to 32 years). Six patients had increases in serum albumin levels but only 4 patients had symptomatic improvement. Systemic side effects included: cushingoid features (5), adrenal insufficiency (4), and new-onset type 2 diabetes mellitus (2). One patient had improvement in cushingoid features after weaning CR-budesonide to 3 mg. Older patients (ages 27 to 32 years) had the worst side effect profiles and were the most refractory to treatment. These patients had sonographic evidence of hepatic cirrhosis but normal serum liver function tests. Two deaths occurred: 1 from sepsis 1 month after CR-budesonide initiation and 1 from respiratory arrest 5 months after CR-budesonide discontinuation. Conclusions. CR-budesonide can be used to treat PLE in certain patients, but careful assessment of hepatic function should be performed before initiation of therapy as systemic side effects can limit treatment. Normal serum liver function tests do not preclude hepatic dysfunction in the Fontan patient, and it is important to perform radiographic assessments as well. (Ann Thorac Surg 2011;92:1451 6) 2011 by The Society of Thoracic Surgeons Protein-losing enteropathy (PLE) is a serious complication of the Fontan operation and has been observed in 5% to 15% of patients after the Fontan procedure [1, 2]. PLE is characterized by the enteric loss of proteins, such as albumin, immunoglobulins, and clotting factors. As a result, patients with PLE can manifest peripheral edema, ascites, immune deficiency, and clotting disorders. Low cardiac output and elevated systemic venous pressures may be two of the mechanisms that contribute to the development of PLE [3 5]. PLE does not develop in most patients who undergo the Fontan procedure; therefore, the exact mechanisms of this complication are poorly understood and the treatment strategies are varied. Oral controlled-released (CR) budesonide, a steroid with low systemic absorption and high enteric activity, has recently been cited as effective treatment for PLE [6]. Accepted for publication March 28, Address correspondence to Dr John, Division of Pediatric Cardiology, Children s National Medical Center, 111 Michigan Ave NW, Washington, DC 20010; anjohn@cnmc.org. The reported advantage of CR-budesonide is that it has low systemic absorption, and theoretically fewer reported systemic side effects, although its use in this patient population is limited and has not been evaluated in the adult population [6]. We review the use of budesonide in the adolescent and adult Fontan population and discuss the side effects, limitations, and usage modification needed in the older Fontan patient. Patients and Methods Data for patients with PLE after the Fontan operation were retrieved from existing clinical databases. We identified 7 patients (4 men) with refractory PLE, treated with CR-budesonide. All patients presented with clinical symptoms of diarrhea, abdominal pain, and fluid retention. The diagnosis of PLE was made through a combination of elevated fecal -1 antitrypsin levels and albumin of less than 3.0 g/dl. The study excluded patients with other primary causes of protein loss, such as nephrotic syndrome or intestinal lymphangiectasia, and 2011 by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur

2 1452 JOHN ET AL Ann Thorac Surg ORAL BUDESONIDE IN PLE AFTER THE FONTAN OPERATION 2011;92: Table 1. Patient Demographics Pt Sex Age (years) Diagnosis Age at Fontan (years) Fontan Type a Age at PLE Diagnosis (years) Age Budesonide Started (years) 1 Female 32 DILV, TGA 12 AP/NF Male 28 Heterotaxy, unbalanced AVC (RV dominant), 4 AP/NF DORV, PA 3 Female 27 DILV, TGA 4 LT/NF Female 20 Tricuspid atresia 4 LT/F Male 19 DILV, TGA 1 LT/NF Male 16 Heterotaxy, dextrocardia, unbalanced AVC (RV 2.5 LT/F 7 13 dominant), DORV, PA 7 Male 17 Unbalanced AVC (RV dominant), aortic coarctation 5 EC/NF a Initial Fontan operation. AP atriopulmonary; AVC atrioventricular canal; DILV double-inlet left ventricle; DORV double-outlet right ventricle; EC extra cardiac; F fenestrated; LT lateral tunnel; NF nonfenestrated; PA pulmonary atresia; PLE protein-losing enteropathy; Pt patient; RV right ventricle; TGA transposition of the great arteries. patients with known inflammatory bowel disease such as Crohn disease or ulcerative colitis. The clinical course of patients, including treatment modalities for PLE, and response to treatment as assessed by laboratory assessment and clinical improvement were recorded. Echocardiograms and cardiac catheterization data were reviewed for valvular regurgitation, ventricular function (visual assessment), cardiac output, intracardiac pressures, and ventricular end-diastolic pressure. Treatment with CR-budesonide was started at 9 mg daily for all patients. The dose in 5 patients was weaned within 6 to 9 months to 3 mg daily or 3 mg every other day. Side effects and exacerbations of PLE occurring during budesonide treatment were recorded. Adrenal insufficiency was determined by symptoms (fatigue, generalized malaise, weakness, nausea, and blood pressure instability) or by low morning serum cortisol levels ( 10 g/dl). Albumin and total protein levels during treatment were recorded and fecal -1 antitrypsin clearance levels were recorded, when available. The protocol was reviewed and approved by the Mayo Foundation Institutional Review Board (Protocol No ). Results Patient Population Patient demographics are summarized in Table 1. Patients were a median age of 20 years (range, 16 to 32 years) at the time of the study. Four patients had a systemic left ventricle and 3 patients had a systemic right ventricle. PLE was diagnosed at a median age of 12 years (range, 2 to 27 years). In patient 5, the PLE developed 1 year after the Fontan completion, whereas PLE was diagnosed in the remaining patients at 7 to 15 years after the operation. All patients had a follow-up clinic visit and laboratory assessment within the past 12 months. Two patients died: patient 2 died of septic shock that occurred 1 month after CR-budesonide initiation, and patient 3 died of acute respiratory distress syndrome 5 months after CR-budesonide was discontinued. Surgical Details Median age at Fontan operation was 4 years (range, 1 to 12 years). The types of Fontan procedures included atriopulmonary connections in 2, lateral tunnel in 4, and extracardiac conduit in 1. Fenestrations were created in 2 patients at the time of their initial Fontan operation and in 3 patients by cardiac catheterization or operation after the PLE diagnosis. Fontan takedown was required in 2 patients. In patient 6, this occurred immediately after the procedure and was palliated with a cavopulmonary anastomoses and an aortic-to-pulmonary artery shunt. PLE was diagnosed 5 years after this palliative procedure. In an attempt to treat the PLE, this patient had a one-and-a-half ventricle repair at age 8, with bilateral bidirectional cavopulmonary shunts, atrial septal defect (ASD) and ventricular septal defect (VSD) closure, and a right ventricle-topulmonary artery conduit. Patient 5 had an initial takedown at age 5, with a subsequent attempt at reestablishing an extracardiac Fontan at age 13. PLE was diagnosed at age 2 years, and the first Fontan takedown was performed as a treatment strategy. The Fontan was taken down again 8 months after the second attempt, and bidirectional cavopulmonary and central shunts were placed. A right axillary vein fistula was eventually placed to improve cardiac output. An additional 2 patients underwent Fontan revisions. Patient 1 underwent a fenestrated, lateral-tunnel Fontan at age 14 years and subsequently had a revision at age 29 years due to refractory arrhythmias and aortic regurgitation. This included an extracardiac, fenestrated Fontan with oversewing of the native aortic valve. Patient 4 underwent revision of her Fontan at age 6 due to a large leak in the Fontan baffle. A small fenestration was created during the revision to an extracardiac conduit. Cardiac Hemodynamics Hemodynamic data are recorded in Table 2. Data from echocardiograms and cardiac catheterization were obtained before budesonide treatment was initiated. Ejec-

3 Ann Thorac Surg JOHN ET AL 2011;92: ORAL BUDESONIDE IN PLE AFTER THE FONTAN OPERATION 1453 Table 2. Hemodynamics Before Budesonide Pt Ventricular EF Ventricular EDP (mm Hg) Cardiac Index (L/min/m 2 ) PA Pressure a (mm Hg) AVVR Aortic or Neoaortic Regurgitation Mild None Trivial None Trivial None None None Mild Mild 6 b Moderate Mild None Moderate a Equivalent to pressures in Fontan pathway. tion fraction was reduced in 3 patients, and the remaining patients had normal ventricular function, with ejection fractions of 0.55 to 0.60 (55% to 60%) by visual estimate. In general, ventricular end-diastolic pressures were within normal range, with a median of 8 mm Hg (range, 7 to 12 mm Hg), and cardiac outputs were in the lower range, with a median of 2.4 L/min/m 2 (range, 1.6 to 2.7 L/min/m 2 ). Efficacy of Budesonide Use Laboratory responses to treatment are summarized in Table 3 and Figure 1. Mean albumin values after 6 months of CR-budesonide therapy were 3.3 g/dl (range 1.7 to 4.1 g/dl), whereas the mean albumin value pretreatment was 2.1 g/dl (range, 1.7 to 2.3 g/dl). Four of the 7 patients reported some symptomatic relief, with less abdominal pain and diarrhea. One patient had relief of pulmonary artery stenosis by stent placement at the same time CR-budesonide treatment was initiated. Dosages were weaned in 6 patients due to medication side effects. Patient 2 died 1 month after budesonide initiation, so weaning did not occur. Controlled-release budesonide was discontinued in 3 patients. Budesonide was weaned and discontinued in 1 patient and then restarted after a PLE exacerbation. PLE b Severe right ventricular-to-pulmonary artery conduit regurgitation. AVVR atrioventricular valve regurgitation; EDP end-diastolic pressure; EF ejection fraction; PA pulmonary artery; Pt patient. exacerbations occurred in 5 patients while they were receiving budesonide treatment, with a subsequent fall in albumin levels despite continuing low-dose budesonide therapy (patient 1) or maintaining a 9-mg dose (Patients 2, 3, 5, 6). Additional Treatment Methods A variety of treatments were used for the patients before budesonide therapy was initiated (Table 4). All patients received heparin, except patient 7 due to a history of heparin-induced thrombocytopenia. At the onset of PLE, 4 patients were diagnosed with hemodynamic Fontan or pulmonary artery obstruction and underwent cardiac catheterization with stent placement in the pulmonary arteries (n 2), in the inferior vena cava (n 1), or by surgical relief of baffle obstruction (n 1). PLE symptoms recurred in 3 patients with Fontan obstruction after relief of the obstruction, and 1 patient underwent stenting of the pulmonary artery at the time of CR-budesonide administration. A total of 5 patients had patent fenestrations, from the initial Fontan procedure in 1 or created subsequent to the diagnosis of PLE in 4. One patient had Fontan takedown and eventual one-and-a-half ventricle repair and did not have a fenestration. Cardiac catheterization interventions Table 3. Patient Response to Budesonide Treatment Prebudesonide Budesonide Therapy a After Exacerbation b Pt Albumin A1AT Albumin A1AT Exacerbations Albumin Current Dose g/dl mg/g g/dl mg/g on Budesonide g/dl (mg/d) Yes 1.9 None NA Yes 1.7 n/a NA Yes 1.3 None NA No c n/a 9 5 d NA Yes 2.2 None NA Yes NA No N/a 3 Mean n/a n/a 1.9 n/a a 6 to 9 months of therapy. b On budesonide therapy. c Total duration of therapy was 6 months. d Weaned off dosage, but restarted due to adrenal insufficiency. A1AT -1 antitrypsin; NA values not available; n/a not applicable; Pt patient.

4 1454 JOHN ET AL Ann Thorac Surg ORAL BUDESONIDE IN PLE AFTER THE FONTAN OPERATION 2011;92: Table 5. Complications During Budesonide Use Patient Complications Infection No Yes No No No No No Cushingoid features Yes No Yes No Yes Yes Yes Osteoporosis/growth Yes No Unk Unk Yes Yes Yes delay Hyperglycemia Yes No Yes No No No No Adrenal insufficiency Yes No Yes Unk Yes Yes No Fig 1. Serum albumin responses to treatment with oral controlledrelease budesonide. included fenestration creation in 3 patients with either a fenestrated ASD device (n 1) or a stent (n 2) to maintain patency. Patient 1 underwent catheterization to reopen a closed fenestration. Sildenafil (10 to 20 mg, three times daily) was used in 5 patients. It was not used in 2 patients due to concerns of hypotension. Usage of the higher 20-mg dose was limited by hypotension in 3 patients. In 1 patient, sildenafil was discontinued at the time of a gastrointestinal hemorrhage. Five patients had dual-chamber pacemakers because of complete heart block (n 3) or bradyarrhythmias/sinus node dysfunction (n 2). In addition, prednisone was used in Patients 5 and 6, overlapping with initial budesonide use. Table 4. Prior Treatment Strategies for Protein-Losing Enteropathy Patient Treatment Strategy Relief of Fontan obstruction No Yes No Yes Yes a No Yes Heparin Yes Yes Yes Yes Yes Yes No Low-fat high-protein diet Yes Yes Yes Yes Yes Yes Yes Anemia therapy Yes Yes Yes Yes Yes Yes No Medications Diuretics Yes Yes Yes Yes Yes Yes Yes ACE inhibitor/arb Yes Yes Yes Yes Yes Yes Yes Aldactone/eplerenone Yes Yes Yes No Yes Yes Yes Antiarrhythmogenics Yes Yes No Sildenafil Yes No Yes b No Yes Yes Yes Pacemaker therapy Yes Yes Yes Yes No No Yes Fontan conversion Yes No No Yes No No No Fenestration No c No Catheter based Yes Yes Yes Yes Surgically created Yes Yes a Pulmonary artery stent. b Sildenafil was stopped at the time of gastrointestinal hemorrhage. c Original fenestrated Fontan taken down. ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker. Unk unknown. Complications All patients had evidence of side effects (Table 5), including cushingoid features in 5, adrenal insufficiency in 4, and infection in 1. These occurred within 3 to 6 months of starting CR-budesonide. Budesonide was weaned because of these side effects, and to date, patients 1 and 3 have been weaned from the medication. CR-budesonide was restarted in patient 5 because of adrenal insufficiency. New-onset diabetes mellitus developed in 2 patients. Growth delay in 2 patients and osteoporosis in 1 were reported, but 2 patients also had a history of prednisone usage overlapping with CR-budesonide initiation. In addition, because no formal testing of bone growth was done before steroids were initiated, the osteoporosis and growth delay could also have been a result of the PLE. Patient 2 died of sepsis that occurred 1 month after budesonide administration. In addition to cushingoid features, myalgias and nonspecific muscular symptoms also developed in patient 7; both side effects improved after budesonide was weaned. Comment Protein-losing enteropathy occurs in 5% to 15% of patients after the modified Fontan operation and is an extremely difficult complication to treat successfully [2, 7]. Numerous theories exist to explain the exact mechanism. Decreased mesenteric blood flow and elevated mesenteric venous pressures may promote systemic inflammation, leading to elevation of inflammatory markers, such as tumor necrosis factor-, and gaps in the intestinal mucosa [8, 9]. The protein loss that occurs leads to the clinical findings of peripheral edema, ascites, diarrhea, weight loss, and malabsorption. Use of oral corticosteroids to target intestinal inflammation has been attempted, but the efficacy was limited due to the significant side effects [10]. Oral CRbudesonide, a steroid that is reported to have 90% first-pass metabolism through the liver, has been used to successfully treat inflammatory bowel disease with relatively low systemic side effects. Thacker and colleagues [6] were the first to report the successful use of CRbudesonide for the treatment of PLE in 9 patients after the Fontan operation. Consistent with the study by Thacker and colleagues, 6 patients in our cohort did have an increase in serum

5 Ann Thorac Surg JOHN ET AL 2011;92: ORAL BUDESONIDE IN PLE AFTER THE FONTAN OPERATION 1455 albumin within 6 months after beginning treatment, but only the 4 youngest patients (aged 16 to 20 years) had symptomatic improvement after starting therapy. Of these 4 patients, 1 had continued improvement in symptoms and side effects with weaning of CR-budesonide. The response to CR-budesonide in the other 3 patients is difficult to assess. One patient had relief of pulmonary artery obstruction simultaneously with CR-budesonide initiation, and the remaining 2 patients were treated with prednisone in addition to the CR-budesonide. Therefore, it is difficult to know whether the improvement in symptoms was due to the CR-budesonide or to the other interventions. Notably, the adult patients (patients 1, 2 and 3) were the most refractory to treatment and none of these patients experienced any improvement in symptoms despite high-dose budesonide therapy. In contrast to the study by Thacker and colleagues, 5 patients in our study had PLE relapses or worsening of PLE while receiving CR-budesonide therapy, despite initially increasing albumin levels. Relapses were defined as worsening edema, ascites, and malaise, with a decrease in serum albumin levels. After relapses, albumin levels were refractory to retreatment with higher-dose CR-budesonide or were much slower to respond than noted during the initial treatment period. The patients who had PLE exacerbations while taking CR-budesonide were also the patients with the worst side effect profile. Certainly, the fluid retention and immune compromises that can result from systemic steroids can worsen the clinical course of a patient with PLE. The use of oral CR-budesonide in our population was limited by the occurrence of systemic side effects. Cushingoid features, adrenal insufficiency, or marked fluid retention developed in all but 2 patients. Although weaning the CR-budesonide dose helped reduce the side effects in the younger patients, profound systemic side effects persisted in the older patients, those aged 27 to 32 years. This was likely due to impaired hepatic clearance of CR-budesonide. In fact, hepatic ultrasound imaging showed the 3 older patients had course echotexture and nodularity consistent with sonographic cirrhosis, but the 3 youngest patients had normal or nonspecific changes. An interesting finding was that liver function test results were normal in our cohort, suggesting that the laboratory assessment of liver function may not be an accurate indictor of hepatic dysfunction in this population. Hepatic dysfunction and progressive fibrosis has been noted after the Fontan operation, and several investigators have reported that cirrhosis and even hepatocellular carcinoma can result [11, 12]. Additional studies have suggested a significant correlation exists between the degree of fibrosis and the duration of time since the Fontan operation. Those with cirrhosis had significantly higher mean hepatic vein pressures [13]. As with PLE, the mechanism is poorly understood, because cirrhosis does not develop in all patients after the Fontan operation. Several other side effects occurred in patients while taking budesonide. Infection occurred in patient 2, and sepsis resulted in death 1 month after budesonide treatment was initiated. This patient had multiple comorbidities, including dialysis-dependent renal failure, a history of sepsis, and refractory arrhythmias; therefore, the relation to budesonide is unknown. PLE might place patients at an increased risk of infection given potential loss of immunoglobulins and an impaired enteric immune system [14, 15]. The addition of CR-budesonide may exacerbate this risk. Other important side effects included hyperglycemia and the development in 2 adult patients of new-onset type 2 diabetes. The decreased hepatic clearance of CR-budesonide in these patients likely contributed to the development of these side effects. Blood glucose levels should be closely monitored during therapy with CR-budesonide. Although CR-budesonide must be used with caution in patients with hepatic dysfunction, there may still be a role for its use in PLE. A recent case report cited intermittent bolus dosing of intravenous and oral steroids as an effective method for PLE treatment in 1 patient [16]. For patients with hepatic dysfunction, this method of treatment might be a potential alternative to avoid long-term systemic side effects. Certainly, additional long-term treatment strategies need to be explored. One patient in our cohort had relief of symptoms with monthly octreotide administration and correction of anemia, and treatment for any sources of gastrointestinal blood loss has also helped stabilize some of our patients [17]. Mortality rates for PLE have been reported to be as high as 50% within 5 years of diagnosis. Of interest in our series, only 2 patients died and 4 patients survived 6 to 17 years after diagnosis. Improvements in medical therapy and continued understanding of the mechanisms of PLE may have resulted in this increased survival. This study has some limitations. This small cohort of 7 patients makes definitive statements difficult. All patients in our series had refractory PLE, and multiple therapies were used before oral CR-budesonide was initiated. The efficacy of budesonide, if begun earlier in the course of PLE, is unknown. In addition, 2 of our younger patients also were receiving systemic steroids intermittently, and 1 patient underwent simultaneous stenting of a pulmonary artery stenosis while taking CR-budesonide. In conclusion, PLE in the cardiac patient remains a difficult complication to treat. Medical management should be aimed at optimizing Fontan hemodynamics, including arrhythmia control, relieving Fontan obstruction, and maximizing cardiac function. CR-budesonide can be an effective treatment for some patients, but use in our older patients with ultrasound evidence of cirrhosis was severely limited due to the systemic absorption and side effect profile. Patients should undergo careful assessment of hepatic function, including laboratory and radiologic testing, before treatment with CR-budesonide is initiated. Budesonide may still have a role in the treatment of PLE in adult patients with hepatic dysfunction, but further study is needed to determine the best strategy of treatment. References 1. Crupi G, Locatelli G, Tiraboschi R, et al. Protein-losing enteropathy after Fontan operation for tricuspid atresia

6 1456 JOHN ET AL Ann Thorac Surg ORAL BUDESONIDE IN PLE AFTER THE FONTAN OPERATION 2011;92: (imperforate tricuspid valve). Thorac Cardiovasc Surg 1980;28: Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996;112: Vyas H, Driscoll DJ, Cabalka AK, Cetta F, Hagler DJ. Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv 2007;69: Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006;82:e Rychik J, Spray TL. Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg 2002;5: Thacker D, Patel A, Dodds K, et al. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010;89: Driscoll DJ, Offord KP, Feldt RH, et al. Five- to fifteen-year follow-up after Fontan operation. Circulation 1992;85: Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002;90: Ryerson L, Goldberg C, Rosenthal A, Armstrong A. Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol 2008;101: Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991;68: Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005;129: Kendall TJ, Stedman B, Hacking N, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol 2008;61: Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. Heart 2007;93: Lenz D, Hambsch J, Schneider P, et al. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 2003;7: Garty BZ. Deficiency of CD4 lymphocytes due to intestinal loss after Fontan procedure. Eur J Pediatr 2001;160: Hoashi T, Ichikawa H, Ueno T, Kogaki S, Sawa Y. Steroid pulse therapy for protein-losing enteropathy after the Fontan operation. Congenit Heart Dis 2009;4: Vyas H, Driscoll DJ, Cetta F, Loftus CG, Connolly HM. Gastrointestinal bleeding and protein-losing enteropathy after the Fontan operation. Am J Cardiol 2006;98: INVITED COMMENTARY Protein-losing enteropathy (PLE) is an enigmatic ailment that strikes children and young adults after a Fontan operation. Over the past 20 years myriad treatments have been proposed ranging from ameliorating the circulatory failure of the Fontan circuit through fenestration creation to the use of medications such as steroidal agents, unfractionated heparin, and high-dose spironolactone. For each of these strategies, great initial enthusiasm has ultimately been tempered by the finding of only modest utility with limited long-term efficacy. Data suggest that inflammation may play an important role in PLE after a Fontan operation. On theoretical grounds, oral controlled-release budesonide is an ideal intestinal antiinflammatory agent. Unlike prednisone, it has high enteric affinity and is 90% metabolized at first pass through the liver, theoretically reducing the risk of steroid-related systemic side effects. Borrowing from a broad experience in children with inflammatory bowel disease, we reported in The Annals of Thoracic Surgery in 2010 on the successful use of budesonide in raising serum protein levels in patients treated at a median age of 15 years (range, 4 to 29 years). John and colleagues [1] from the Mayo Clinic now report their experience with budesonide in a group of patients treated at a median age of 20 years (range, 16 to 32 years) They found a high rate of steroid-related side effects as well as a high rate of treatment failure. The high rate of side effects likely reflects indolent progressive hepatic dysfunction related to time after Fontan operation. The high failure rate suggests a resistance to disease treatment in those with long-standing illness, perhaps related to chronic changes in the gut lumen over time. The growing experience with oral budesonide as treatment for PLE provides a number of lessons. There is clearly a subgroup of patients who respond well, with the ability to wean to low doses with improvement in symptoms and quality of life, and a subgroup that does not respond. Budesonide is a potentially useful agent but should be tried with caution. If serious side effects are noted, or no response is seen within a limited time (3 to 6 months), weaning and discontinuation is indicated. More effective strategies for this debilitating disease await a clearer fundamental understanding of the mechanism of the disorder, which to date continues to elude us. Jack Rychik, MD Division of Cardiology The Cardiac Center at The Children s Hospital of Philadelphia 34th and Civic Center Blvd Philadelphia, PA rychik@ .chop.edu Reference 1. John AS, Driscoll DJ, Warnes CA, Phillips SD, Cetta F. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2011;92: by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur

Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation

Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Appendix A.1: Tier 1 Surgical Procedure Terms and Definitions

Appendix A.1: Tier 1 Surgical Procedure Terms and Definitions Appendix A.1: Tier 1 Surgical Procedure Terms and Definitions Tier 1 surgeries AV Canal Atrioventricular Septal Repair, Complete Repair of complete AV canal (AVSD) using one- or two-patch or other technique,

More information

Pediatric Echocardiography Examination Content Outline

Pediatric Echocardiography Examination Content Outline Pediatric Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 Anatomy and Physiology Normal Anatomy and Physiology 10% 2 Abnormal Pathology and Pathophysiology

More information

LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE

LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE S Bruce Greenberg, MD, FACR, FNASCI Professor of Radiology and Pediatrics Arkansas Children's Hospital University of Arkansas for Medical Sciences

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACHD. See Adult congenital heart disease (ACHD) Adult congenital heart disease (ACHD), 503 512 across life span prevalence of, 504 506

More information

Fontan Deterioration in Pediatric Cardiologist s s View. Pusan National University Hospital Hyoung Doo Lee M.D.

Fontan Deterioration in Pediatric Cardiologist s s View. Pusan National University Hospital Hyoung Doo Lee M.D. Fontan Deterioration in Pediatric Cardiologist s s View Pusan National University Hospital Hyoung Doo Lee M.D. Outcomes of Fontan operation JTCS 2006:131;172-80 Mitchell ME et al Jan. 1992~Dec. 1999, 332

More information

The evolution of the Fontan procedure for single ventricle

The evolution of the Fontan procedure for single ventricle Hemi-Fontan Procedure Thomas L. Spray, MD The evolution of the Fontan procedure for single ventricle cardiac malformations has included the development of several surgical modifications that appear to

More information

Glenn Shunts Revisited

Glenn Shunts Revisited Glenn Shunts Revisited What is a Super Glenn Patricia O Brien, MSN, CPNP-AC Nurse Practitioner, Pediatric Cardiology No Disclosures Single Ventricle Anatomy Glenn Shunt Cavopulmonary Anastomosis Anastomosis

More information

Cardiac Catheterization Cases Primary Cardiac Diagnoses Facility 12 month period from to PRIMARY DIAGNOSES (one per patient)

Cardiac Catheterization Cases Primary Cardiac Diagnoses Facility 12 month period from to PRIMARY DIAGNOSES (one per patient) PRIMARY DIAGNOSES (one per patient) Septal Defects ASD (Atrial Septal Defect) PFO (Patent Foramen Ovale) ASD, Secundum ASD, Sinus venosus ASD, Coronary sinus ASD, Common atrium (single atrium) VSD (Ventricular

More information

When to implant an ICD in systemic right ventricle?

When to implant an ICD in systemic right ventricle? When to implant an ICD in systemic right ventricle? Département de rythmologie et de stimulation cardiaque Nicolas Combes n.combes@clinique-pasteur.com Pôle de cardiologie pédiatrique et congénitale Risk

More information

Outline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease

Outline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease Special Considerations for Special Populations: Congenital Heart Disease Valerie Bosco, FNP, EdD Alison Knauth Meadows, MD, PhD University of California San Francisco Adult Congenital Heart Program Outline

More information

Adult Echocardiography Examination Content Outline

Adult Echocardiography Examination Content Outline Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,

More information

Survival Rates of Children with Congenital Heart Disease continue to improve.

Survival Rates of Children with Congenital Heart Disease continue to improve. DOROTHY RADFORD Survival Rates of Children with Congenital Heart Disease continue to improve. 1940-20% 1960-40% 1980-70% 2010->90% Percentage of children with CHD reaching age of 18 years 1938 First Patent

More information

Adults with Congenital Heart Disease. Michael E. McConnell MD, Wendy Book MD Teresa Lyle RN NNP

Adults with Congenital Heart Disease. Michael E. McConnell MD, Wendy Book MD Teresa Lyle RN NNP Adults with Congenital Heart Disease Michael E. McConnell MD, Wendy Book MD Teresa Lyle RN NNP Outline History of CHD Statistics Specific lesions (TOF, TGA, Single ventricle) Erythrocytosis Pregnancy History

More information

Heart Transplantation in Patients with Superior Vena Cava to Pulmonary Artery Anastomosis: A Single-Institution Experience

Heart Transplantation in Patients with Superior Vena Cava to Pulmonary Artery Anastomosis: A Single-Institution Experience Korean J Thorac Cardiovasc Surg 2018;51:167-171 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) CLINICAL RESEARCH https://doi.org/10.5090/kjtcs.2018.51.3.167 Heart Transplantation in Patients with Superior

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Children with Single Ventricle Physiology: The Possibilities

Children with Single Ventricle Physiology: The Possibilities Children with Single Ventricle Physiology: The Possibilities William I. Douglas, M.D. Pediatric Cardiovascular Surgery Children s Memorial Hermann Hospital The University of Texas Health Science Center

More information

Early outcome after Fontan operation for univentricular

Early outcome after Fontan operation for univentricular Thrombus Formation After the Fontan Operation Patrick D. Coon, RDCS, RCVT, Jack Rychik, MD, Rita T. Novello, RDCS, Pamela S. Ro, MD, J. William Gaynor, MD, and Thomas L. Spray, MD Cardiac Center at the

More information

The Fontan circulation. Folkert Meijboom

The Fontan circulation. Folkert Meijboom The Fontan circulation Folkert Meijboom What to expect? Why a Fontan-circulation Indications How does it work Types of Fontan circulation Historical overview Role of echocardiography What to expect? Why

More information

Common Defects With Expected Adult Survival:

Common Defects With Expected Adult Survival: Common Defects With Expected Adult Survival: Bicuspid aortic valve :Acyanotic Mitral valve prolapse Coarctation of aorta Pulmonary valve stenosis Atrial septal defect Patent ductus arteriosus (V.S.D.)

More information

Adult Congenital Heart Disease: What All Echocardiographers Should Know Sharon L. Roble, MD, FACC Echo Hawaii 2016

Adult Congenital Heart Disease: What All Echocardiographers Should Know Sharon L. Roble, MD, FACC Echo Hawaii 2016 1 Adult Congenital Heart Disease: What All Echocardiographers Should Know Sharon L. Roble, MD, FACC Echo Hawaii 2016 DISCLOSURES I have no disclosures relevant to today s talk 2 Why should all echocardiographers

More information

Management of Heart Failure in Adult with Congenital Heart Disease

Management of Heart Failure in Adult with Congenital Heart Disease Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form

More information

Absent Pulmonary Valve Syndrome

Absent Pulmonary Valve Syndrome Absent Pulmonary Valve Syndrome Fact sheet on Absent Pulmonary Valve Syndrome In this condition, which has some similarities to Fallot's Tetralogy, there is a VSD with narrowing at the pulmonary valve.

More information

Surgical Management of Failing Fontan Operation

Surgical Management of Failing Fontan Operation Surgical Management of Failing Fontan Operation Jeong-Jun Park Dept. of Thoracic & cardiovascular Surgery Asan Medical Center, Ulsan University Fontan operation 1995-2001, 123 procedures in 71 pts EJCTS

More information

Introduction. Study Design. Background. Operative Procedure-I

Introduction. Study Design. Background. Operative Procedure-I Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic

More information

Use of the Total Artificial Heart in the Failing Fontan Circulation J William Gaynor, M.D.

Use of the Total Artificial Heart in the Failing Fontan Circulation J William Gaynor, M.D. Use of the Total Artificial Heart in the Failing Fontan Circulation J William Gaynor, M.D. Daniel M. Tabas Endowed Chair in Pediatric Cardiothoracic Surgery at The Children s Hospital of Philadelphia The

More information

TGA atrial vs arterial switch what do we need to look for and how to react

TGA atrial vs arterial switch what do we need to look for and how to react TGA atrial vs arterial switch what do we need to look for and how to react Folkert Meijboom, MD, PhD, FES Dept ardiology University Medical entre Utrecht The Netherlands TGA + atrial switch: Follow-up

More information

Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!

Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'

More information

Anatomy & Physiology

Anatomy & Physiology 1 Anatomy & Physiology Heart is divided into four chambers, two atrias & two ventricles. Atrioventricular valves (tricuspid & mitral) separate the atria from ventricles. they open & close to control flow

More information

CONGENITAL HEART DEFECTS IN ADULTS

CONGENITAL HEART DEFECTS IN ADULTS CONGENITAL HEART DEFECTS IN ADULTS THE ROLE OF CATHETER INTERVENTIONS Mario Carminati CONGENITAL HEART DEFECTS IN ADULTS CHD in natural history CHD with post-surgical sequelae PULMONARY VALVE STENOSIS

More information

Mechanical Support in the Failing Fontan-Kreutzer

Mechanical Support in the Failing Fontan-Kreutzer Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University

More information

Perioperative Management of DORV Case

Perioperative Management of DORV Case Perioperative Management of DORV Case James P. Spaeth, MD Department of Anesthesia Cincinnati Children s Hospital Medical Center University of Cincinnati Objectives: 1. Discuss considerations regarding

More information

3/14/2011 MANAGEMENT OF NEWBORNS CARDIAC INTENSIVE CARE CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 WITH HEART DEFECTS

3/14/2011 MANAGEMENT OF NEWBORNS CARDIAC INTENSIVE CARE CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 WITH HEART DEFECTS CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 MANAGEMENT OF NEWBORNS WITH HEART DEFECTS A NTHONY C. CHANG, MD, MBA, MPH M E D I C AL D I RE C T OR, HEART I N S T I T U T E C H I LDRE N

More information

Congenital heart disease: When to act and what to do?

Congenital heart disease: When to act and what to do? Leading Article Congenital heart disease: When to act and what to do? Duminda Samarasinghe 1 Sri Lanka Journal of Child Health, 2010; 39: 39-43 (Key words: Congenital heart disease) Congenital heart disease

More information

5.8 Congenital Heart Disease

5.8 Congenital Heart Disease 5.8 Congenital Heart Disease Congenital heart diseases (CHD) refer to structural or functional heart diseases, which are present at birth. Some of these lesions may be discovered later. prevalence of Chd

More information

ECHOCARDIOGRAPHIC APPROACH TO CONGENITAL HEART DISEASE: THE UNOPERATED ADULT

ECHOCARDIOGRAPHIC APPROACH TO CONGENITAL HEART DISEASE: THE UNOPERATED ADULT ECHOCARDIOGRAPHIC APPROACH TO CONGENITAL HEART DISEASE: THE UNOPERATED ADULT Karen Stout, MD, FACC Divisions of Cardiology University of Washington Medical Center Seattle Children s Hospital NO DISCLOSURES

More information

Impact of the Evolution of the Fontan Operation on Early and Late Mortality: A Single-Center Experience of 405 Patients Over 3 Decades

Impact of the Evolution of the Fontan Operation on Early and Late Mortality: A Single-Center Experience of 405 Patients Over 3 Decades Impact of the Evolution of the Fontan Operation on Early and Late Mortality: A Single-Center Experience of 405 Patients Over 3 Decades Hideo Ohuchi, MD, PhD, Koji Kagisaki, MD, Aya Miyazaki, MD, Masataka

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,

More information

Dual Chamber Epicardial Pacing for the Failing Atriopulmonary Fontan Patient

Dual Chamber Epicardial Pacing for the Failing Atriopulmonary Fontan Patient Dual Chamber Epicardial Pacing for the Failing Atriopulmonary Fontan Patient Ali Dodge-Khatami, MD, PhD, Mariette Rahn, MD, René Prêtre, MD, and Urs Bauersfeld, MD Divisions of Cardiovascular Surgery and

More information

Screening for Critical Congenital Heart Disease

Screening for Critical Congenital Heart Disease Screening for Critical Congenital Heart Disease Caroline K. Lee, MD Pediatric Cardiology Disclosures I have no relevant financial relationships or conflicts of interest 1 Most Common Birth Defect Most

More information

Congenital Heart Disease in the Adult Presenting for Non-Cardiac Surgery

Congenital Heart Disease in the Adult Presenting for Non-Cardiac Surgery Page 1 Congenital Heart Disease in the Adult Presenting for Non-Cardiac Surgery Susan S. Eagle, M.D. Nashville, Tennessee Introduction: Advancement of surgical techniques and medical management patients

More information

Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum

Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum Kagami MIYAJI, MD, Akira FURUSE, MD, Toshiya OHTSUKA, MD, and Motoaki KAWAUCHI,

More information

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5 National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION CPT Codes: 93451, 93452, 93453, 93454, 93455, 93456, 93457, 93458, 93459, 93460, 93461 LCD ID Number:

More information

Protein-losing enteropathy (PLE) is a rare but

Protein-losing enteropathy (PLE) is a rare but PROTEIN-LOSING ENTEROPATHY AFTER THE FONTAN OPERATION: AN INTERNATIONAL MULTICENTER STUDY Luc Mertens, MD, PhD a Donald J. Hagler, MD b Ursula Sauer, MD c Jane Somerville, MD d Marc Gewillig, MD, PhD a

More information

Cardiac MRI in ACHD What We. ACHD Patients

Cardiac MRI in ACHD What We. ACHD Patients Cardiac MRI in ACHD What We Have Learned to Apply to ACHD Patients Faris Al Mousily, MBChB, FAAC, FACC Consultant, Pediatric Cardiology, KFSH&RC/Jeddah Adjunct Faculty, Division of Pediatric Cardiology

More information

SURGICAL TREATMENT AND OUTCOME OF CONGENITAL HEART DISEASE

SURGICAL TREATMENT AND OUTCOME OF CONGENITAL HEART DISEASE SURGICAL TREATMENT AND OUTCOME OF CONGENITAL HEART DISEASE Mr. W. Brawn Birmingham Children s Hospital. Aims of surgery The aim of surgery in congenital heart disease is to correct or palliate the heart

More information

September 26, 2012 Philip Stockwell, MD Lifespan CVI Assistant Professor of Medicine (Clinical)

September 26, 2012 Philip Stockwell, MD Lifespan CVI Assistant Professor of Medicine (Clinical) September 26, 2012 Philip Stockwell, MD Lifespan CVI Assistant Professor of Medicine (Clinical) Advances in cardiac surgery have created a new population of adult patients with repaired congenital heart

More information

Management of a Patient after the Bidirectional Glenn

Management of a Patient after the Bidirectional Glenn Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe

More information

CMR for Congenital Heart Disease

CMR for Congenital Heart Disease CMR for Congenital Heart Disease * Second-line tool after TTE * Strengths of CMR : tissue characterisation, comprehensive access and coverage, relatively accurate measurements of biventricular function/

More information

T who has survived first-stage palliative surgical management

T who has survived first-stage palliative surgical management Intermediate Procedures After First-Stage Norwood Operation Facilitate Subsequent Repair Richard A. Jonas, MD Department of Cardiac Surgery, Children s Hospital, Boston, Massachusetts Actuarial analysis

More information

Multimodality Imaging of Septal Defects

Multimodality Imaging of Septal Defects Multimodality Imaging of Septal Defects Ohio-ACC 2018 Annual Meeting October 27, 2018 Kan N. Hor, MD Director, Cardiac Magnetic Resonance Imaging Associate Professor of Pediatrics The Heart Center, Nationwide

More information

Antithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki

Antithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from

More information

For Personal Use. Copyright HMP 2013

For Personal Use. Copyright HMP 2013 12-00415 Case Report J INVASIVE CARDIOL 2013;25(4):E69-E71 A Concert in the Heart. Bilateral Melody Valve Implantation in the Branch Pulmonary Arteries Nicola Maschietto, MD, PhD and Ornella Milanesi,

More information

A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution

A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution Original Article A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution Ghassan Baslaim, MD, and Jill Bashore, RN Purpose: Adult patients with congenital

More information

Heart and Lungs. LUNG Coronal section demonstrates relationship of pulmonary parenchyma to heart and chest wall.

Heart and Lungs. LUNG Coronal section demonstrates relationship of pulmonary parenchyma to heart and chest wall. Heart and Lungs Normal Sonographic Anatomy THORAX Axial and coronal sections demonstrate integrity of thorax, fetal breathing movements, and overall size and shape. LUNG Coronal section demonstrates relationship

More information

Septal Defects. How does the heart work?

Septal Defects. How does the heart work? Septal Defects How does the heart work? The heart is the organ responsible for pumping blood to and from all tissues of the body. The heart is divided into right and left sides. The job of the right side

More information

The Adolescent and Adult Congenital Heart Disease Program

The Adolescent and Adult Congenital Heart Disease Program The Adolescent and Adult Congenital Heart Disease Program The Heart Center at Nationwide Children s Hospital & The Ohio State University D- Transposition of the Great Vessels D- transposition of the great

More information

Intracardiac Lateral Tunnel Fontan by using Right Atrial Wall

Intracardiac Lateral Tunnel Fontan by using Right Atrial Wall Intracardiac Lateral Tunnel Fontan by using Right Atrial Wall Md Zahidul Islam¹, AM Asif Rahim², Kazi Abul Hasan¹, Syed Imtiaz Ahsan¹ 1 Department of Paediatric Cardiac Surgery, National Institute of Cardiovascular

More information

Complex Congenital Heart Disease in Adults

Complex Congenital Heart Disease in Adults Complex Congenital Heart Disease in Adults Linda B. Haramati, MD Disclosures Complex Congenital Heart Disease in Adults Linda B. Haramati MD, MS Jeffrey M. Levsky MD, PhD Meir Scheinfeld MD, PhD Department

More information

Total Cavopulmonary Connections in Children With a Previous Norwood Procedure

Total Cavopulmonary Connections in Children With a Previous Norwood Procedure Total Cavopulmonary Connections in Children With a Previous Norwood Procedure Anthony Azakie, MD, Brian W. McCrindle, MD, FRCP(C), Lee N. Benson, MD, FRCP(C), Glen S. Van Arsdell, MD, Jennifer L. Russell,

More information

cctga patients need lifelong follow-up in an age-appropriate facility with expertise in

cctga patients need lifelong follow-up in an age-appropriate facility with expertise in ONLINE SUPPLEMENT ONLY: ISSUES IN THE ADULT WITH CCTGA General cctga patients need lifelong follow-up in an age-appropriate facility with expertise in congenital heart disease care at annual intervals.

More information

Recent technical advances and increasing experience

Recent technical advances and increasing experience Pediatric Open Heart Operations Without Diagnostic Cardiac Catheterization Jean-Pierre Pfammatter, MD, Pascal A. Berdat, MD, Thierry P. Carrel, MD, and Franco P. Stocker, MD Division of Pediatric Cardiology,

More information

Although most patients with Ebstein s anomaly live

Although most patients with Ebstein s anomaly live Management of Neonatal Ebstein s Anomaly Christopher J. Knott-Craig, MD, FACS Although most patients with Ebstein s anomaly live through infancy, those who present clinically as neonates are a distinct

More information

Atrioventricular Valve Dysplasia

Atrioventricular Valve Dysplasia Atrioventricular Valve Dysplasia How does the heart work? The heart is the organ responsible for pumping blood to and from all tissues of the body. The heart is divided into right and left sides. The job

More information

Congenital Heart Defects

Congenital Heart Defects Normal Heart Congenital Heart Defects 1. Patent Ductus Arteriosus The ductus arteriosus connects the main pulmonary artery to the aorta. In utero, it allows the blood leaving the right ventricle to bypass

More information

What is the Definition of Small Systemic Ventricle. Hong Ryang Kil, MD Department of Pediatrics, College of Medicine, Chungnam National University

What is the Definition of Small Systemic Ventricle. Hong Ryang Kil, MD Department of Pediatrics, College of Medicine, Chungnam National University What is the Definition of Small Systemic Ventricle Hong Ryang Kil, MD Department of Pediatrics, College of Medicine, Chungnam National University Contents Introduction Aortic valve stenosis Aortic coarctation

More information

Deok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION

Deok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION Deok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION Carpentier classification Chauvaud S, Carpentier A. Multimedia Manual of Cardiothoracic Surgery 2007

More information

Surgical procedures based on the Fontan principle separate

Surgical procedures based on the Fontan principle separate Clinical Outcome of Fenestrated Fontan Patients After Closure The First 10 Years Donna A. Goff, MS; Elizabeth D. Blume, MD; Kimberlee Gauvreau, ScD; John E. Mayer, MD; James E. Lock, MD; Kathy J. Jenkins,

More information

FUNCTIONALLY SINGLE VENTRICLE

FUNCTIONALLY SINGLE VENTRICLE MORPHOLOGICAL DETERMINANTS VI TRAN EuroEcho, Budapest, 7 th December 2011 DECLARATION OF CONFLICT OF INTEREST: I have nothing to declare What is the functionally single ventricle? The heart that is incapable

More information

Coarctation of the aorta

Coarctation of the aorta T H E P E D I A T R I C C A R D I A C S U R G E R Y I N Q U E S T R E P O R T Coarctation of the aorta In the normal heart, blood flows to the body through the aorta, which connects to the left ventricle

More information

Accuracy of the Fetal Echocardiogram in Double-outlet Right Ventricle

Accuracy of the Fetal Echocardiogram in Double-outlet Right Ventricle Blackwell Publishing IncMalden, USACHDCongenital Heart Disease 2006 The Authors; Journal compilation 2006 Blackwell Publishing, Inc.? 200723237Original ArticleFetal Echocardiogram in Double-outlet Right

More information

M/3, cc-tga, PS, BCPC(+) Double Switch Operation

M/3, cc-tga, PS, BCPC(+) Double Switch Operation 2005 < Pros & Cons > M/3, cc-tga, PS, BCPC(+) Double Switch Operation Congenitally corrected TGA Atrio-Ventricular & Ventriculo-Arterial discordance Physiologically corrected circulation with the morphologic

More information

Echocardiography of Congenital Heart Disease

Echocardiography of Congenital Heart Disease Echocardiography of Congenital Heart Disease Sunday, April 15 Tuesday, April 17, 2018 Ruth and Tristram Colket, Jr. Translational Research Building on the Raymond G. Perelman Campus Learn more: chop.cloud-cme.com

More information

A National Cardiogenic Shock Initiative (CSI):

A National Cardiogenic Shock Initiative (CSI): A National Cardiogenic Shock Initiative (CSI): Insights from the Impella Quality (IQ) Program, cvad Registry and the Detroit CSI Experience William O Neill, MD, FACC Medical Director Structural Heart Disease

More information

The Double Switch Using Bidirectional Glenn and Hemi-Mustard. Frank Hanley

The Double Switch Using Bidirectional Glenn and Hemi-Mustard. Frank Hanley The Double Switch Using Bidirectional Glenn and Hemi-Mustard Frank Hanley No relationships to disclose CCTGA Interesting Points for Discussion What to do when. associated defects must be addressed surgically:

More information

Anesthetic Considerations in Adults with Congenital Heart Disease

Anesthetic Considerations in Adults with Congenital Heart Disease CRASH Vail, Colorado 2018 Colorado Review of Anesthesia for SurgiCenters and Hospitals and Ski Holiday! CRASH Vail, Colorado 2018 Colorado Review of Anesthesia for SurgiCenters and Hospitals Anesthetic

More information

CHD. Amir A. Ghaferi, BS, and Grover M. Hutchins, MD

CHD. Amir A. Ghaferi, BS, and Grover M. Hutchins, MD Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma Amir A. Ghaferi, BS, and Grover

More information

Heart and Soul Evaluation of the Fetal Heart

Heart and Soul Evaluation of the Fetal Heart Heart and Soul Evaluation of the Fetal Heart Ivana M. Vettraino, M.D., M.B.A. Clinical Associate Professor, Michigan State University College of Human Medicine Objectives Review the embryology of the formation

More information

Adult Congenital Heart Disease: A Growing Problem. Dr. Gary Webb Cincinnati Children s Hospital Heart Institute

Adult Congenital Heart Disease: A Growing Problem. Dr. Gary Webb Cincinnati Children s Hospital Heart Institute Adult Congenital Heart Disease: A Growing Problem Dr. Gary Webb Cincinnati Children s Hospital Heart Institute ACHD Resources in Ohio ACHAHEART.ORG Situations When We Might Help When you don t know a

More information

The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients

The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients The Turkish Journal of Pediatrics 2008; 50: 549-553 Original The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients Selman Vefa Yıldırım 1, Kürşad

More information

Glenn and Fontan Caths:

Glenn and Fontan Caths: Glenn and Fontan Caths: Pre-operative evaluation and Trouble-shooting Cavo-Pulmonary Shunts Daniel H. Gruenstein, M.D. Director, Pediatric Interventional Cardiology University of Minnesota Children s Hospital,

More information

Echocardiographic assessment in Adult Patients with Congenital Heart Diseases

Echocardiographic assessment in Adult Patients with Congenital Heart Diseases Echocardiographic assessment in Adult Patients with Congenital Heart Diseases Athanasios Koutsakis Cardiologist, Cl. Research Fellow George Giannakoulas Ass. Professor in Cardiology 1st Cardiology Department,

More information

Adult Congenital Heart Disease T S U N ` A M I!

Adult Congenital Heart Disease T S U N ` A M I! Adult Congenital Heart Disease T S U N ` A M I! Erwin Oechslin, MD, FRCPC, FESC Director, Congenital Cardiac Centre for Adults University Health Network Peter Munk Cardiac Centre / Toronto General Hospital

More information

Congenital Heart Disease II: The Repaired Adult

Congenital Heart Disease II: The Repaired Adult Congenital Heart Disease II: The Repaired Adult Doreen DeFaria Yeh, MD FACC Assistant Professor, Harvard Medical School MGH Adult Congenital Heart Disease Program Echocardiography Section, no disclosures

More information

MEDICAL MANAGEMENT WITH CAVEATS 1. In one study of 50 CHARGE patients with CHD, 75% required surgery. 2. Children with CHARGE may be resistant to chlo

MEDICAL MANAGEMENT WITH CAVEATS 1. In one study of 50 CHARGE patients with CHD, 75% required surgery. 2. Children with CHARGE may be resistant to chlo CARDIOLOGY IN CHARGE SYNDROME: FOR THE PHYSICIAN Angela E. Lin, M.D. Teratology Program/Active Malformation Surveillance, Brigham and Women's Hospital, Old PBBH-B501, 75 Francis St., Boston, MA 02115 alin@partners.org

More information

Adults with Congenital Heart Disease

Adults with Congenital Heart Disease Adults with Congenital Heart Disease Edward K. Rhee, MD, FACC Director, Pediatric-Adult Congenital Arrhythmia Service SJHMC Disclosures & Disclaimer I have no lucrative financial relationships with industry

More information

The complications of cardiac surgery:

The complications of cardiac surgery: The complications of cardiac surgery: a walk on the Dark Side? Prof Rik De Decker Red Cross Children s Hospital CME Nov/Dec 2011 http://www.cmej.org.za Why should you care? You are about to leave your

More information

Congenital Heart Disease

Congenital Heart Disease Congenital Heart Disease Mohammed Alghamdi, MD, FRCPC, FAAP, FACC Associate Professor and Consultant Pediatric Cardiology, Cardiac Science King Fahad Cardiac Centre King Saud University INTRODUCTION CHD

More information

CYANOTIC CONGENITAL HEART DISEASES. PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU

CYANOTIC CONGENITAL HEART DISEASES. PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU CYANOTIC CONGENITAL HEART DISEASES PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU DEFINITION Congenital heart diseases are defined as structural and functional problems of the heart that are

More information

Changing Profile of Adult Congenital Heart Disease

Changing Profile of Adult Congenital Heart Disease Congenital Heart Disease New Developments for the General Cardiologist Changing Profile of Adult Congenital Heart Disease European Society of Cardiology August 27, 2012 Ariane Marelli MD, FRCP, FACC, MPH

More information

Research Presentation June 23, Nimish Muni Resident Internal Medicine

Research Presentation June 23, Nimish Muni Resident Internal Medicine Research Presentation June 23, 2009 Nimish Muni Resident Internal Medicine Research Question In adult patients with repaired Tetralogy of Fallot, how does Echocardiography compare to MRI in evaluating

More information

Medical Management of Acute Heart Failure

Medical Management of Acute Heart Failure Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training

More information

Congenital heart disease. By Dr Saima Ali Professor of pediatrics

Congenital heart disease. By Dr Saima Ali Professor of pediatrics Congenital heart disease By Dr Saima Ali Professor of pediatrics What is the most striking clinical finding in this child? Learning objectives By the end of this lecture, final year student should be able

More information

Data Collected: June 17, Reported: June 30, Survey Dates 05/24/ /07/2010

Data Collected: June 17, Reported: June 30, Survey Dates 05/24/ /07/2010 Job Task Analysis for ARDMS Pediatric Echocardiography Data Collected: June 17, 2010 Reported: Analysis Summary For: Pediatric Echocardiography Exam Survey Dates 05/24/2010-06/07/2010 Invited Respondents

More information

Transcatheter closure of interatrial

Transcatheter closure of interatrial 372 Br HeartJf 1994;72:372-377 PRACTICE REVIEWED Department of Paediatric Cardiology, Royal Brompton Hospital, London A N Redington M L Rigby Correspondence to: Dr A N Redington, Department of Paediatric

More information

9/8/2009 < 1 1,2 3,4 5,6 7,8 9,10 11,12 13,14 15,16 17,18 > 18. Tetralogy of Fallot. Complex Congenital Heart Disease.

9/8/2009 < 1 1,2 3,4 5,6 7,8 9,10 11,12 13,14 15,16 17,18 > 18. Tetralogy of Fallot. Complex Congenital Heart Disease. Current Indications for Pediatric CTA S Bruce Greenberg Professor of Radiology Arkansas Children s Hospital University of Arkansas for Medical Sciences greenbergsbruce@uams.edu 45 40 35 30 25 20 15 10

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

MEDICAL SCIENCES Vol.I -Adult Congenital Heart Disease: A Challenging Population - Khalid Aly Sorour

MEDICAL SCIENCES Vol.I -Adult Congenital Heart Disease: A Challenging Population - Khalid Aly Sorour ADULT CONGENITAL HEART DISEASE: A CHALLENGING POPULATION Khalid Aly Sorour Cairo University, Kasr elaini Hospital, Egypt Keywords: Congenital heart disease, adult survival, specialized care centers. Contents

More information

Unbalanced AVC: When is it Time to Bail?

Unbalanced AVC: When is it Time to Bail? Unbalanced AVC: When is it Time to Bail? David M. Overman Division of Pediatric Cardiac Surgery The Children s Heart Clinic Chief, Division of Cardiovascular Surgery Children s Hospitals and Clinics of

More information

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac

More information